A triple-negative breast cancer face-off
Duelling pivotal trials of anti-TROP2 ADCs should yield their first data imminently.
Merck seeks the next Keytruda
The group’s Kelun-partnered TROP2 ADC looks like a bargain, but Merck’s pipeline has big shoes to fill.
ASCO 2024 – full Evoke-01 result adds to Gilead’s Trodelvy problems
Gilead came out swinging in second-line lung cancer, but it might have just whiffed.
Astra starts a pivotal lung cancer combo
Tropion-Lung10 will combine dato-dxd with rilvegostomig, and focus on PD-L1 and TROP2 expression.
